Your browser doesn't support javascript.
loading
Fc-modified HIT-like monoclonal antibody as a novel treatment for sepsis.
Gollomp, Kandace; Sarkar, Amrita; Harikumar, Sanjiv; Seeholzer, Steven H; Arepally, Gowthami M; Hudock, Kristin; Rauova, Lubica; Kowalska, M Anna; Poncz, Mortimer.
Afiliação
  • Gollomp K; Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA.
  • Sarkar A; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Harikumar S; Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA.
  • Seeholzer SH; Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA.
  • Arepally GM; Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA.
  • Hudock K; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Rauova L; Deparment of Medicine, Duke University School of Medicine, Durham, NC.
  • Kowalska MA; Department of Internal Medicine, University of Cincinnati School of Medicine, Cincinnati, OH; and.
  • Poncz M; Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA.
Blood ; 135(10): 743-754, 2020 03 05.
Article em En | MEDLINE | ID: mdl-31722003
Sepsis is characterized by multiorgan system dysfunction that occurs because of infection. It is associated with high morbidity and mortality and is in need of improved therapeutic interventions. Neutrophils play a crucial role in sepsis, releasing neutrophil extracellular traps (NETs) composed of DNA complexed with histones and toxic antimicrobial proteins that ensnare pathogens, but also damage host tissues. At presentation, patients often have a significant NET burden contributing to the multiorgan damage. Therefore, interventions that inhibit NET release would likely be ineffective at preventing NET-based injury. Treatments that enhance NET degradation may liberate captured bacteria and toxic NET degradation products (NDPs) and likely be of limited therapeutic benefit as well. We propose that interventions that stabilize NETs and sequester NDPs may be protective in sepsis. We showed that platelet factor 4 (PF4), a platelet-associated chemokine, binds and compacts NETs, increasing their resistance to DNase I. We now show that PF4 increases NET-mediated bacterial capture, reduces the release of NDPs, and improves outcome in murine models of sepsis. A monoclonal antibody KKO which binds to PF4-NET complexes, further enhances DNase resistance. However, the Fc portion of this antibody activates the immune response and increases thrombotic risk, negating any protective effects in sepsis. Therefore, we developed an Fc-modified KKO that does not induce these negative outcomes. Treatment with this antibody augmented the effects of PF4, decreasing NDP release and bacterial dissemination and increasing survival in murine sepsis models, supporting a novel NET-targeting approach to improve outcomes in sepsis.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoglobulina G / Sepse / Anticorpos Monoclonais Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: Blood Ano de publicação: 2020 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoglobulina G / Sepse / Anticorpos Monoclonais Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: Blood Ano de publicação: 2020 Tipo de documento: Article País de publicação: Estados Unidos